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Introduction
An important goal of DMPK scientists in drug discovery is to be able to predict human pharmacokinetic (PK) and dosing regimen using in vitro data from human-derived reagents such as hepatocytes and liver microsomes. To increase high confidence in prediction, it is desirable to accurately predict PK parameters for the same compound (s) in at least two preclinical species, typically rat and dog using corresponding in vitro reagents from three species (Wilby et al., 2011) . Therefore, developing in vitro -in vivo correlation (IVIVC) in preclinical species is highly valuable in order to gain confidence in human translation.
Clearance is one of the most challenging PK parameters to accurately predict due to species differences in drug metabolizing enzymes, potential for multiple metabolic pathways, as well as contribution of drug transport. Chemical series that demonstrate strong IVIVC in preclinical species (e.g., rat, dog) are more likely to give reliable prediction of human clearance from in vitro data (Wilby et al., 2011) . For low clearance compounds (defined as intrinsic clearance is not measurable using standard liver microsomal or hepatocyte assays), however, in vitro hepatic clearance values are not usually available due to lack of appropriate tools in assessing poorly metabolized compounds in drug discovery. This leads to insufficient supporting evidence of adequate IVIVC from preclinical species, and therefore low confidence in human translation.
In drug discovery, low intrinsic clearance compounds have increased significantly over the years due to the effective use of high throughput ADMET screening and early DMD#53322 metabolite identification, which enable rapid SAR to address high intrinsic clearance as a liability . In addition, new chemical space of drug discovery is being explored, such as liver targeting (Oballa et al., 2011; Pfefferkorn et al., 2012) and once weekly dosing (Rangan et al., 2007) , and all these require low clearance. While low clearance can be a beneficial attribute in a new drug to increase exposure, prolong halflife and reduce dose, it presents a challenge for DMPK scientists, because tools available in drug discovery to accurately measure low clearance are limited. As a consequence, it is often inaccurately assumed that no metabolism is occurring when intrinsic clearance is below the limit of in vitro microsomal or hepatocyte stability assays. This frequently leads to inaccurate prediction of human clearance, half-life and dose. To address low clearance challenges, the hepatocyte relay method was recently developed to predict human intrinsic clearance for low intrinsic clearance compounds . In this study, we have expanded the hepatocyte relay method to predict rat and dog intrinsic clearance in order to establish IVIVC in three preclinical species to support high confidence translation of human IVIVC for low clearance compounds. This is the first in vitro tool available to study low clearance in rat and dog when limited to measure intrinsic clearance by monitoring substrate depletion.
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Material and Methods
Materials
Test compounds were obtained from Pfizer Global Material Management (Groton, CT) or purchased from Sigma-Aldrich (St. Louis, MO). Other reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless specified. 96-well polypropylene plates were from Thermo (Pittsburgh, PA) and 24-well polystyrene plates were obtained from Costar (Sigma-Aldrich, St. Louis, MO) .
Rat and Dog Hepatocyte Relay Method
The rat and dog hepatocyte relay methods are similar to the human hepatocyte relay assay previously reported . Pooled cryopreserved male beagle dog hepatocytes from 5 dogs and male Wistar-Han rat hepatocytes from 12 rats were purchased from Celsis IVT (Baltimore, MD). Upon thawing, the hepatocytes were re-suspended in Williams E medium (WEM GIBCO-BRL, cat#C1984, custom formula # 91-5233EC) supplemented with 50 mM HEPES and 26 mM Na 2 CO 3 . The cells were counted using the Trypan Blue exclusion method, and the 24-well hepatocyte plates containing 0.5 million cells/mL were spiked with a compound at a final concentration of 1 M (final DMSO of 0.025% and MeOH of 0.125%), in a final incubation volume of 0.50 mL. The plates were covered with Breathe-Easy TM gas permeable membranes or equivalent (Diversified Biotech, Dedham, MA) and incubated at 37C with 95% O 2 / 5% CO 2 , 75% relative humidity for 4 hours at 150 rpm on an orbital shaker in an incubator. At time 0 and 4 hr, 25 µL of hepatocyte suspension was removed from the incubation and added to 50 µL of cold acetonitrile containing internal standard to quench the reaction. The DMD#53322 samples were centrifuged (Eppendorf, Hauppauge, NY) at 3000 rpm for 10 minutes at RT and 50 µL supernatant was transferred to a clean plate, dried completely and reconstituted in 50% methanol / 50% water prior to LC/MS/MS analysis. The remaining hepatocyte suspension in the incubation plate was centrifuged (3000 rpm , 10 minutes, RT) and 25 uL supernatant removed and added to 50 µL cold aceontitrile containing internal standard to determine the concentration of the supernatant. 300 µL of the remaining supernatant was transferred to a clean 24-well plate and stored at -80C until the next relay experiment. For the 2 nd relay experiment, the supernatant plates were warmed to 37C for 30 min and hepatocytes were added to the samples to yield a final cell density 0.5 million cells/mL. The plates were incubated at 37C for 4 hr, sampled and processed as described above. Five relays were performed to give a total incubation time of 20 hr. Buffer control plate (without hepatocytes) was run under the same conditions to monitor any non-metabolic decline. Standard curves were prepared using the same matrix material.
LC/MS/MS Quantification
The LC mobile phases were: (A) HPLC grade water containing 0.1% formic acid; and (B) acetonitrile containing 0.1% formic acid or (A) 95% 2 mM ammonium acetate in water and 5% 50/50 methanol/acetonitrile and (B) 90% 50/50 methanol/acetonitrile and 10% 2 mM ammonium acetate in water. A solvent gradient from 5% (B) to 95% (B) over 2.0 minutes at the flow rate of 0.5 mL/min was used to elute the compounds from the column (Kinetex C18, 30x2 mm, 2.6μm, Phenomenex, Torrance, CA). The cycletime was 3 minutes / injection. An aliquot of 15 μL sample was injected for analysis 
Calculations
The data transformation and calculation for the hepatocyte relay assay has been discussed previously . The hepatocyte relay assay requires transfer of the supernatant between plates for the different relay incubations. Drug is lost due to hepatocyte uptake, nonspecific binding, or other sources, and dilution of the drug occurs as new hepatocytes and medium are added post transfer. These losses necessitate a correction before comparison to time zero concentrations. The correction equation follows (Eq. 1):
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Here, C corrected is the total concentration of the well after transfer corrected for loss and dilution. Recovery accounts for the fraction of the compound irretrievable due to nonspecific binding to the well or other sources, and should be set to unity unless it is known that drug is lost after each transfer at a location not captured in the totalconcentration measurement. Recovery can be estimated experimentally by measuring the change in concentration of a representative solution from before and after addition to a well in the absence of cells (buffer control) . N is the number of transfers. The ratio of the well volume to the supernatant-transfer volume corrects for the dilution which occurs after each transfer. The above equation assumes that the ratio is fixed, i.e. the total and transfer volume remain constant throughout the relay assay. Deviations can be handled by Eq. 2. The final term, the product of the ratios of the total and supernatant concentrations in the steps previous to the transfer corrects for loss in the hepatocyte precipitate. The corrected values can be compared directly to values obtained at early time points prior to any transfer.
Half-life was calculated using Eq. 3 and intrinsic clearance was obtained using Eq. 4 for rat and Eq. 5 for dog with the corrected concentration (C corrected ) discussed above (Hosea et al., 2009 In vivo intrinsic clearance was calculated using the well-stirred model (Ashforth et al., 1995) (Eq. 6) based on in vivo IV plasma clearance data from the literature, where Q H is hepatic blood flow (70 and 40 ml/min/kg for rat and dog, respectively); CL b is hepatic blood clearance; fu p is fraction unbound in plasma; R B is blood to plasma concentration ratio.
Results
A set of low clearance compounds in rat and dog was selected for the study based on available literature data and low intrinsic hepatic metabolic clearance values. In vivo IV clearance values were obtained from the literature and hepatic clearance values were calculated by subtracting renal and biliary clearance from plasma clearance. Variability of the in vivo data can lead to disconnect of IVIVC. IV data from multiple strains were used assuming strain difference in clearance to be minimal (Richmond et al., 2010) . No oral PK data was included in order to ensure data quality. In vivo intrinsic clearance was calculated from in vivo hepatic clearance using the well-stirred model (Hallifax et al., 2010) by incorporating literature or in-house plasma protein binding and blood-to-plasma ratio. Intrinsic clearance values from hepatocyte relay were obtained using five relays (20 hour accumulative incubation time) with 0.5 million cell density per mL and were reported as mean values of two or three replicates. All test compounds had significant turnover under the assay conditions and demonstrated good linearity. Hepatocyte binding was not incorporated for correction of unbound intrinsic clearance, since all the compounds have f u,hep close to 1 based on the calculated values (Kilford et al., 2008) estimated using Log P/D from ACD software.
Rat IVIVC for Low Clearance Compounds
The intrinsic clearance values of rat from both in vivo and the in vitro hepatocyte relay method are summarized in Table 1 . The in vivo rat intrinsic clearance values ranged from 4 to 2000 mL/min/Kg. The in vivo literature clearance values were from a variety of rat strains (e.g., Sprague-Dawley, Wistar, Fischer) and both genders, since not all the DMD#53322 compounds had data from Wistar Han rat. Strain and gender difference in drug metabolism was assumed to be minimal (Richmond et al., 2010) , though exceptions do exist for certain compounds. The hepatocytes used in the rat relay assay were Wistar Han, which was a standard strain for the Pfizer internal rat hepatocyte stability assay. In general, most compounds showed good IVIVC with the in vitro hepatocyte relay assay within 2-3 fold of in vivo intrinsic clearance values (Figure 1) . The exceptions had a high hepatic uptake component by transporters (e.g., fexofenadine (Poirier et al., 2009 ), fluvastatin , ketoprofen (Morita et al., 2005) , prazosin (Qin et al., 1994) , and bosentan (Huang et al., 2012) ) or potential contribution from extra-hepatic metabolism [e.g., hydrolysis of acebutolol (Andresen and Davis, 1979), UGT metabolism of ketoprofen (Terrier et al., 1999) ].
Dog IVIVC for Low Clearance Compounds
The intrinsic clearance values of dog from both in vivo and the in vitro hepatocyte relay method are summarized in Table 2 
Human IVIVC for Low Clearance Compounds
Human IVIVC of low clearance compounds using the hepatocyte relay method has been reported previously . Additional low clearance compounds with rat and dog data were included in this study for cross-species IVIVC (Table 3 ). Figure 1 shows all the IVIVC data from this and previous study . All the compounds showed good IVIVC between in vivo human intrinsic clearance and the hepatocyte relay method, with the exception of ketoprofen.
This article has not been copyedited and formatted. The final version may differ from this version. There were no adequate in vitro tools to determine low clearance in drug discovery. If a compound has no measurable turnover in liver microsomes or hepatocytes under the standard assay conditions, compounds would be reported as having no metabolism or below a certain cutoff clearance value. The development of the hepatocyte relay method enables determination of clearance values for low clearance compounds early in drug discovery to support SAR, prioritization of chemical series, and for human PK and dose projection . The hepatocyte relay method has been shown to correlate well with in vivo human intrinsic clearance. Here, the IVIVC in rat and dog was evaluated for low clearance compounds to assess application of the method in preclinical species.
Typically, the hepatocyte relay method used an incubation time of 20 hours, which allowed an estimation of half-life in hepatocytes up to 40 hours (Di et al., 2004 ). In theory, the limit of the low clearance value that can be measured decreases with increasing number of relays. However, based on the theoretical calculation, intrinsic clearance values drop most significantly for the first few relays. As incubation time goes beyond 20 hrs, there is little gain in clearance values from each additional relay.
Therefore, in practice, five relays are the standard assay conditions used to support drug discovery programs. To achieve lower limit of intrinsic clearance, one approach is the DMD#53322 increase the cell density in the incubation when hepatocyte binding is low. For example, the intrinsic clearance of antipyrine in human was determined using 2.0 million cell/mL in this study due to the very low clearance.
As shown in Tables 1-3 and Figure 1 , the rat, dog and human hepatocyte relay method gave good prediction of in vivo intrinsic clearance [additional human data was collected during this study and added to the previously published set ]. For most compounds, the in vivo and in vitro intrinsic clearance ratios were within 2-fold, suggesting good IVIVC. The exceptions involved significant active uptake from transporters or contribution of extra-hepatic metabolism. Figure 2 shows the IVIVC of five compounds with rat, dog and human data. Good human IVIVC was observed when both rat and dog demonstrated strong IVIVC (i.e., ranitidine, tolbutamide, antipyrine, and naproxen). For ketoprofen, the rank-order of the species is correct, the in vivo values are under-predicted. About 5-fold under-prediction of human in vivo intrinsic clearance was observed for ketoprofen. Correction factor derived from rat and dog can be applied to enhance human prediction accuracy of intrinsic clearance. Weak or no IVIVC in preclinical species often translated to low confident prediction of human in vivo clearance from in vitro data.
In rat, significant contribution of transporter mediated clearance was observed for ketoprofen (Poirier et al., 2009 ), leading to under-prediction of in vivo clearance based on metabolic clearance from hepatocytes since transporter uptake also contributes the systemic clearance (Yamazaki et al., 1996; Shitara et al., 2006; Watanabe et al., 2010b) .
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In addition, potential extra-hepatic contribution of UGT metabolism in rat can lead to under-prediction of in vivo clearance (Terrier et al., 1999) . In dog, the major elimination pathway for ketoprofen was through UGT metabolism and kidney had a significant contribution to the metabolism (Granero and Amidon, 2008) . In human, ketoprofen was mainly metabolized by CYP2C9 and UGT2B7 (Kilford et al., 2009 ). The extra-hepatic contribution of UGT metabolism could potentially contribute to the under-prediction of intrinsic clearance using hepatocytes for ketoprofen.
This study indicated that the rat and dog hepatocyte relay method gave good prediction of in vivo hepatic clearance for low clearance compounds. The hepatocyte relay method extended the low limit for intrinsic clearance measurement by about 10-fold, which enhanced our ability to address the challenges of low intrinsic clearance compounds. The good in vivo prediction of the rat and dog hepatocyte relay method on clearance highlights the wide applications of the relay approach not only in human clearance prediction , but also in preclinical species.
This article has not been copyedited and formatted. The final version may differ from this version. 
Conclusions
Rat and dog hepatocyte relay method has been successfully developed and applied to predict in vivo clearance for low clearance compound. Good IVIVC was observed for most of the compounds with in vivo to in vitro intrinsic clearance ratio within 2-fold. The outliers were due to the contribution of transporter mediated clearance or extra-hepatic metabolism. This is the first method available to study low clearance compounds in rat and dog in drug discovery. It highlights the broad applications of the hepatocyte relay method in preclinical species as well as human for developing IVIVC. 7.4 ± 0.6 1.0
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